Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Natera, Inc. - Common Stock (NQ:NTRA)

165.60 +3.65 (+2.25%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Natera, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Natera Technology Featured in 300+ Peer-Reviewed Publications, Underscoring Scientific Leadership in Precision Medicine
From Natera, Inc.
Via Business Wire
Natera Launches Proprietary AI Foundation Models to Accelerate Diagnostic and Therapeutic Innovation
From Natera, Inc.
Via Business Wire
1 Healthcare Stock to Own for Decades and 2 We Find Risky
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged recently as players offloaded surplus COVID... 
Via StockStory
Topics Retirement Stocks
5 Analysts Have This To Say About Natera
 
Via Benzinga
How Is The Market Feeling About Natera?
 
Via Benzinga
IMvigor011 Bladder Cancer Trial Achieves Positive Results, with Signatera™ Strongly Predicting Adjuvant Immunotherapy Benefit
From Natera, Inc.
Via Business Wire
$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today
 
Via Benzinga
NTRA Q2 Deep Dive: Oncology Growth, Product Innovation, and Margin Pressures
Genetic testing company Natera (NASDAQ:NTRA). reported Q2 CY2025 results exceeding the market’s revenue expectations, with sales up 32.2% year on year to $546.6 million. The company’s full-year revenue... 
Via StockStory
Topics Artificial Intelligence
2 Mid-Cap Stocks on Our Watchlist and 1 We Brush Off
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract... 
Via StockStory
Earnings Scheduled For August 7, 2025
 
Via Benzinga
How Do Investors Really Feel About Natera?
 
Via Benzinga
1 of Wall Street’s Favorite Stock to Own for Decades and 2 We Turn Down
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because... 
Via StockStory
Tech Stocks Eye Record Highs As Magnificent Seven Top $19.5 Trillion: What's Moving Markets Friday?
Tech stocks staged a full rebound from last Friday's sell-off, with the Nasdaq 100 surging to 23,600 — just shy of the 23,700 all-time high set in late July, as the week’s strong sector earnings and... 
Via Benzinga
Why Are Natera (NTRA) Shares Soaring Today
Shares of genetic testing company Natera (NASDAQ:NTRA). jumped 11.6% in the morning session after it reported strong second-quarter 2025 financial results, including a significant revenue beat and... 
Via StockStory
Topics Earnings World Trade
SoundHound AI, Ouster, Globalstar, Doximity, JFrog And Other Big Stocks Moving Higher On Friday
 
Via Benzinga
Topics Artificial Intelligence
Natera (NASDAQ:NTRA) Delivers Strong Q2 Numbers, Stock Jumps 12.6%
Genetic testing company Natera (NASDAQ:NTRA). reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 32.2% year on year to $546.6 million. The company’s full-year revenue... 
Via StockStory
Natera NTRA Q2 2025 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Natera (NTRA) Q2 Revenue Jumps 32%
Via The Motley Fool
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Natera Reports Second Quarter 2025 Financial Results
From Natera, Inc.
Via Business Wire
Natera Launches Fetal Focus™: A Noninvasive Prenatal Test for Inherited Conditions
From Natera, Inc.
Via Business Wire
What To Expect From Natera’s (NTRA) Q2 Earnings
Genetic testing company Natera (NASDAQ:NTRA). will be announcing earnings results this Thursday after market hours. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence
Natera Highlights Latest Prospera™ Data at WTC 2025; 16 Abstracts Including Five Oral Presentations
From Natera, Inc.
Via Business Wire
Natera to Report Its Second Quarter Results on August 7, 2025
From Natera, Inc.
Via Business Wire
Natera Announces Launch of ABCSG 61 (“TEODOR”), a Randomized Controlled Trial of Signatera™ in Early-Stage Breast Cancer
From Natera, Inc.
Via Business Wire
$100 Invested In Natera 5 Years Ago Would Be Worth This Much Today
 
Via Benzinga
PEDAL Study Successful, Shows Monitoring with Prospera™ Kidney Provides Accurate Prognosis of Long-Term Clinical Outcomes Following Rejection; Now Published in AJT
From Natera, Inc.
Via Business Wire
Schlumberger, Stellantis And ASML Holding Are Among Top 10 Large Cap Losers Last Week (July 14-July 18): Are The Others In Your Portfolio?
Elevance Health and Waters led the weekly large-cap losers, hit by weak earnings, lowered guidance, and analyst downgrades. 
Via Benzinga
$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
 
Via Benzinga
1 Unprofitable Stock for Long-Term Investors and 2 to Approach with Caution
Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure. 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.